Patients taking Novo Nordisk's Wegovy obesity treatment maintained an average of 10% weight loss after four years, ...
A recent US study has found that weight loss medications like Wegovy and Ozempic may increase the risk of abdominal paralysis ...
The results shed light on the long-term effects of Wegovy, and could boost Novo Nordisk's case to insurers and governments to ...
A Novo spokesperson said in a statement to Reuters that the new analysis "demonstrates for the first time the benefits of ...
Wegovy, a relatively new drug approved by the US Food and Drug Administration (FDA) in June 2021, mimics the body’s GLP-1 ...
The data could go some way to convince insurers and governments to reimburse Wegovy. Read more at straitstimes.com.
The anti-diabetic medication “Ozempic” (semaglutide) made by Danish pharmaceutical company “Novo Nordisk”on February 23, 2023 ...
Novo Nordisk (NVO) claims it retains only 60% of list price of weight loss drugs Ozempic and Wegovy after payments to pharma ...
Global spending on obesity medications totaled $24 billion last year, IQVIA estimated in its latest five-year outlook, and ...
The study found that the majority of people on Wegovy lost weight, on average 10% of their body weight, in the first 15 ...
Patients sometimes have to stop using GLP-1 medications like Ozempic and Wegovy and risk regaining lost weight.
Novo Nordisk, maker of the blockbuster drugs for diabetes and weight loss respectively, has a market capitalisation of ...